Santhera Pharmaceuticals Holding AG (S3F0) H1 Revenue CHF 48.3M; Guides CHF 80—90M FY

Santhera reported H1 2026 revenue of CHF 48.3M and a net loss of CHF -21.5M, and reiterated 2026 revenue guidance of CHF 80—90M with opex of CHF 50—55M.Material DetailsContext by AI AnalystThis is mid-cycle confirmation of commercial rollout momentum for AGAMREE with improving P&L but reliance on m…